Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma

Gynecologic Oncology

Volumn 134, Issue 3, 2014, Pages 591-598

  Cohen, Samantha ^a   Mosig, Rebecca ^a   Moshier, Erin ^a   Pereira, Elena ^a   Rahaman, Jamal ^a   Prasad Hayes, Monica ^a   Halpert, Richard ^b   Billaud, Jean Noel ^b   Dottino, Peter ^a   Martignetti, John A ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b Qiagen Bioinformatics   (United States)

Author keywords

Biomarker; Cisplatin resistance; IRF1; Ovarian cancer; Survival

Indexed keywords

CISPLATIN; INTERFERON REGULATORY FACTOR 1; TRANSCRIPTOME; ANTINEOPLASTIC AGENT; BIOLOGICAL MARKER; IRF1 PROTEIN, HUMAN;

ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER PROGNOSIS; CANCER RESISTANCE; CANCER SURVIVAL; CARCINOGENESIS; CHEMOSENSITIVITY; CLINICAL ARTICLE; CLINICAL FEATURE; CYTOREDUCTIVE SURGERY; FEMALE; GENETIC DIFFERENCE; HIGH GRADE SEROUS OVARIAN CANCER; HUMAN; HUMAN TISSUE; IMMUNOREGULATION; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA SEQUENCE; CISPLATIN-RESISTANCE; CYSTADENOCARCINOMA; DISEASE FREE SURVIVAL; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; MORTALITY; OVARY TUMOR; PHYSIOLOGY; PROGNOSIS; SURVIVAL; SURVIVAL RATE;

BIOMARKER; CISPLATIN-RESISTANCE; IRF1; OVARIAN CANCER; SURVIVAL;

ANTINEOPLASTIC AGENTS; CISPLATIN; CYSTADENOCARCINOMA, SEROUS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON REGULATORY FACTOR-1; MIDDLE AGED; OVARIAN NEOPLASMS; PROGNOSIS; SURVIVAL RATE;

EID: 84908318355     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2014.06.025     Document Type: Article

References (28)

1. Siegel, R., Naishadham, D., Jemal, A., Cancer statistics, 2013. CA Cancer J Clin 63 (2013), 11–30.
2. Kotsopoulos, J., Moody, J.R., Fan, I., Rosen, B., Risch, H.A., McLaughlin, J.R., et al. Height, weight, BMI and ovarian cancer survival. Gynecol Oncol 127 (2012), 83–87.
3. Darcy, K.M., Birrer, M.J., Translational research in the Gynecologic Oncology Group: evaluation of ovarian cancer markers, profiles, and novel therapies. Gynecol Oncol 117 (2010), 429–439.
4. Baldwin, L.A., Huang, B., Miller, R.W., Tucker, T., Goodrich, S.T., Podzielinski, I., et al. Ten-year relative survival for epithelial ovarian cancer. Obstet Gynecol 120 (2012), 612–618.
5. Colombo, N., Gore, M., Treatment of recurrent ovarian cancer relapsing 6–12 months post platinum-based chemotherapy. Crit Rev Oncol Hematol 64 (2007), 129–138.
6. Monk, B.J., Herzog, T.J., Kaye, S.B., Krasner, C.N., Vermorken, J.B., Muggia, F.M., et al. Trabectedin plus pegylated liposomal doxorubicin (PLD) versus PLD in recurrent ovarian cancer: overall survival analysis. Eur J Cancer 48 (2012), 2361–2368.
7. Chien, J., Kuang, R., Landen, C., Shridhar, V., Platinum-sensitive recurrence in ovarian cancer: the role of tumor microenvironment. Front Oncol, 3, 2013, 251.
8. Colombo, P.E., Fabbro, M., Theillet, C., Bibeau, F., Rouanet, P., Ray-Coquard, I., Sensitivity and resistance to treatment in the primary management of epithelial ovarian cancer. Crit Rev Oncol Hematol 89 (2013), 207–216.
9. Windbichler, G.H., Hausmaninger, H., Stummvoll, W., Graf, A.H., Kainz, C., Lahodny, J., et al. Interferon-gamma in the first-line therapy of ovarian cancer: a randomized phase III trial. Br J Cancer 82 (2000), 1138–1144.
10. Alberts, D.S., Marth, C., Alvarez, R.D., Johnson, G., Bidzinski, M., Kardatzke, D.R., et al. Randomized phase 3 trial of interferon gamma-1b plus standard carboplatin/paclitaxel versus carboplatin/paclitaxel alone for first-line treatment of advanced ovarian and primary peritoneal carcinomas: results from a prospectively designed analysis of progression-free survival. Gynecol Oncol 109 (2008), 174–181.
11. Zeimet, A.G., Reimer, D., Wolf, D., Fiegl, H., Concin, N., Wiedemair, A., et al. Intratumoral interferon regulatory factor (IRF)-1 but not IRF-2 is of relevance in predicting patient outcome in ovarian cancer. Int J Cancer 124 (2009), 2353–2360.
12. Taniguchi, T., Lamphier, M.S., Tanaka, N., IRF-1: the transcription factor linking the interferon response and oncogenesis. Biochim Biophys Acta 1333 (1997), M9–M17.
13. Kroger, A., Koster, M., Schroeder, K., Hauser, H., Mueller, P.P., Activities of IRF-1. J Interferon Cytokine Res 22 (2002), 5–14.
14. Pavan, S., Olivero, M., Cora, D., Di Renzo, M.F., IRF-1 expression is induced by cisplatin in ovarian cancer cells and limits drug effectiveness. Eur J Cancer 49 (2013), 964–973.
15. Mosig, R.A., Lobl, M., Senturk, E., Shah, H., Cohen, S., Chudin, E., et al. IGFBP-4 tumor and serum levels are increased across all stages of epithelial ovarian cancer. J Ovarian Res, 5, 2012, 3.
16. Trapnell, C., Pachter, L., Salzberg, S.L., TopHat: discovering splice junctions with RNA-Seq. Bioinformatics 25 (2009), 1105–1111.
17. Trapnell, C., Williams, B.A., Pertea, G., Mortazavi, A., Kwan, G., van Baren, M.J., et al. Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. Nat Biotechnol 28 (2010), 511–515.
18. Gentleman, R., Bioinformatics and computational biology solutions using R and bioconductor limma: linear models for microarray data. 2005.
19. Sun, Z., Asmann, Y.W., Kalari, K.R., Bot, B., Eckel-Passow, J.E., Baker, T.R., et al. Integrated analysis of gene expression, CpG island methylation, and gene copy number in breast cancer cells by deep sequencing. PLoS One, 6, 2011, e17490.
20. Gyorffy, B., Lanczky, A., Szallasi, Z., Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. Endocr Relat Cancer 19 (2012), 197–208.
21. Tothill, R.W., Tinker, A.V., George, J., Brown, R., Fox, S.B., Lade, S., et al. Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 14 (2008), 5198–5208.
22. Hacker, N.F., Berek, J.S., Lagasse, L.D., Nieberg, R.K., Elashoff, R.M., Primary cytoreductive surgery for epithelial ovarian cancer. Obstet Gynecol 61 (1983), 413–420.
23. Frumovitz, M., Schmeler, K.M., Malpica, A., Sood, A.K., Gershenson, D.M., Unmasking the complexities of mucinous ovarian carcinoma. Gynecol Oncol 117 (2010), 491–496.
24. Sabbatini, P., Odunsi, K., Immunologic approaches to ovarian cancer treatment. J Clin Oncol 25 (2007), 2884–2893.
25. Chen, Y.L., Cheng, W.F., Chang, M.C., Lin, H.W., Huang, C.T., Chien, C.L., et al. Interferon-gamma in ascites could be a predictive biomarker of outcome in ovarian carcinoma. Gynecol Oncol 131 (2013), 63–68.
26. Zhang, L., Conejo-Garcia, J.R., Katsaros, D., Gimotty, P.A., Massobrio, M., Regnani, G., et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 348 (2003), 203–213.
27. Schwartz, J.L., Shajahan, A.N., Clarke, R., The role of interferon regulatory factor-1 (IRF1) in overcoming antiestrogen resistance in the treatment of breast cancer. Int J Breast Cancer, 2011, 2011, 912102.
28. Tanaka, N., Ishihara, M., Kitagawa, M., Harada, H., Kimura, T., Matsuyama, T., et al. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell 77 (1994), 829–839.